This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma